Progress of targeted therapy for multiple myeloma

doi:10.3877.cma.j.issn.2095-5820.2015.03.006

Abstract

Abstract:

In recent years, the treatment of multiple myeloma (MM) has progressed from the era of chemotherapy into the targeted therapy times, the targeted therapy focus on inhibiting the myeloma cell growth and survival in the bone marrow microenvironment. With the further investigation of MM, numerous novel agents and new regimens of combined chemotherapy are currently emerging. The clinical application of Immunomodulatory drugs (IMids), proteasome inhibitor based single or combined regimens has had profound effects a MM therapy, which promises for MM patients.

Key words: Multiple myeloma, Immunomodulatory drugs, Proteasome inhibitors, Monoclonal antibody

Xiaolei Chen, Wenming Chen. Progress of targeted therapy for multiple myeloma[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2015, 03(03): 160-167.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877.cma.j.issn.2095-5820.2015.03.006

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2015/V03/I03/160

References 18

[1]	Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J].J Clin Oncol, 2002, 20(22):4420–4427.
[2]	Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26):2609–2617.
[3]	Jagannath S, Barlogie B,Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J]. Br J Hematol, 2004, 127(2):165–172.
[4]	Richardson PG, Sonneveld P,Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24):2487–2498.
[5]	Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial[J]. Blood, 2007, 110(10):3557–3560.
[6]	Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma[J]. Br J Haematol, 2009, 144(6):887–894.
[7]	Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma[J]. J Clin Oncol, 2008, 26(29):4777–4783.
[8]	San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma[J]. J Clin Oncol, 2013, 31(4):448–455.
[9]	Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients[J]. Blood, 2009, 114(27):5436–5443.
[10]	Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2015, 372(2):142–152.
[11]	Richardson PG, Baz R,Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients[J]. Blood, 2014, 124(7):1038–1046.
[12]	Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis[J]. Leukemia, 2011, 25(4):689–696.
[13]	McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366(19):1770–1781.
[14]	San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(11):1055–1066.
[15]	Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial[J]. Br J Haematol, 2008, 143(2):191–200.
[16]	Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma[J].Br J Haematol, 2012, 156(4):552–555.
[17]	Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease[J]. Br J Haematol, 2011, 155(5):632–634.
[18]	San-Miguel JF, Hungria VT,Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1195–1206.

Please choose a citation manager

Content to export